newsio aggregates and links to original sources. We do not own the original images or content. If you believe content infringes on intellectual property rights, contact us — it will be removed at first notice.
biotech/news//Benzinga
Pfizer shares were down 1.3% at $25.70 at the time of publication on Monday.
Pfizer's berobenatide showed a 15.9% non-placebo-adjusted weight loss at 32 weeks in Phase 2b.
KEY POINTS
Pfizer presented first clinical results with berobenatide's top weekly dose at this update.
The pivotal Phase 3 trial for berobenatide is now enrolling participants for obesity treatment.
Pfizer plans ten additional Phase 3 studies of berobenatide in 2026 targeting various comorbidities.
HYMPAVZI's FDA indication now includes pediatric hemophilia B patients aged 6 to 11 years.
Pfizer Berobenatide Update
On Saturday, the company reported that the Phase 2b studies for berobenatide demonstrated a non-placebo-adjusted weight loss of 15.9% in participants.
The pivotal Phase 3 study is currently open for enrollment, which may further bolster Pfizer’s position in the obesity treatment market.
Pfizer plans to advance 10 Phase 3 studies for berobenatide in 2026 for chronic weight management and obesity-related comorbidities, including knee osteoarthritis and obstructive sleep apnea, as part of a broader program of 20+ obesity trials.
The first clinical experience with the top weekly dose for berobenatide is were presented for the first time.
Results from a 32-week exploratory extension (Part B) of the Phase 2b VESPER-1 study showed a non-placebo-adjusted weight loss of 15.9% with no plateau observed at 32 weeks on berobenatide (Week 60 of the overall study), in participants who escalated from placebo to 2.4 mg weekly berobenatide.
Phase 3 Program Expands
FDA Expands HYMPAVZI Indication
HYMPAVZI is the first subcutaneous non-factor therapy available for pediatric patients with hemophilia B aged 6 to 11 years.
PFE Stock Price Activity: Pfizer shares were down 1.3% at $25.70 at the time of publication on Monday, according to Benzinga Pro data.
Photo: Molly Woodward / Shutterstock